Valion Bio names Lisa Wolf president and COO, adds two directors
The Nasdaq-listed biotech also disclosed a $7.74 million financing with 3i, LP tied to overdue payments under its Series C preferred stock terms.
Valion Bio, Inc. (Nasdaq: VBIO) announced management and board changes in an 8-K dated August 27, 2026 and a press release dated September 1, 2026. The Board unanimously appointed Lisa Wolf to the expanded roles of President and Chief Operating Officer, effective immediately, with Wolf continuing as CFO and taking on executive leadership following the departure of former CEO Michael K. Handley.1
The company also added two new directors. The board appointed Jared Malbin effective August 27, 2026.1 Malbin has more than 25 years in financial services and has served since 2024 as Chief Operating Officer of Lucid Capital Markets, LLC, a boutique investment banking broker-dealer.1
Thomas Jensen was also appointed to the board effective August 27, 2026.1 Since December 2023, Jensen has served as CEO of Allarity Therapeutics, Inc. (Nasdaq: ALLR), where he oversees development of stenoparib, described as a "dual PARP/WNT inhibitor," in a Phase 2 program for advanced ovarian cancer.1
Separately, the filing disclosed a financing arrangement with investor 3i, LP. On August 31, 2026, the company and 3i entered a letter agreement under which Valion agreed to issue 100 Series B Preferred Shares, warrants for 3,077 shares of common stock at $3.62 per share, 7,637 Series C Preferred Shares, and warrants for 1,053,969 shares of common stock at $3.62 per share, for an aggregate purchase price of $7,737,000.1 Of that amount, $6,137,000 was to be retained by 3i to cover overdue cash true-up payments under the Series C Certificate of Designation, $100,000 was to cover 3i's legal fees, and $1,500,000 was to be paid to the company in cash.1 The share and price figures reflect Valion's 1-for-25 reverse stock split effective August 31, 2026.1
Valion's lead program remains Entolimod, a Toll-like Receptor 5 agonist being developed as a potential medical countermeasure for Acute Radiation Syndrome under the FDA's Animal Rule, designed to activate NF-κB signaling pathways tied to cellular protection, tissue recovery and immune response.1 The candidate has received Fast Track and Orphan Drug designations from the FDA.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.